Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30914672 | 1.00 | MAPK1 (0.40) | MAPK1NNMTHCAR3MGLLKDM4E | |
| Hydrochloric Acid SCHEMBL310253 | 0.99 | MAPK1 (0.39) | MAPK1NNMTHCAR3MGLLKDM4E | |
| Hydrochloric Acid SCHEMBL30019344 | 0.99 | MAPK1 (0.39) | MAPK1NNMTHCAR3MGLLKDM4E | |
| Acetone SCHEMBL1019109 | 0.96 | MAPK1 (0.40) | MAPK1NNMTHCAR3MGLLKDM4E | |
| Acetone SCHEMBL17732269 | 0.95 | MAPK1 (0.39) | MAPK1NNMTHCAR3MGLLKDM4E | |
| SCHEMBL28248952 | 0.91 | NNMT (0.38) | MAPK1NNMTHCAR3KDM4EGAA | |
| SCHEMBL1509187 | 0.87 | MAPK1 (0.41) | MAPK1NNMTHCAR3MGLLKDM4E | |
| Hydrochloric Acid SCHEMBL5087052 | 0.86 | MAPK1 (0.40) | MAPK1NNMTHCAR3MGLLKDM4E | |
| SCHEMBL16938414 | 0.82 | GABRP (0.49) | MAPK1NNMTMGLLKDM4EGAA | |
| SCHEMBL14603527 | 0.82 | HCAR3 (0.38) | MAPK1NNMTHCAR3MGLLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022221706-A1 | METHODS FOR ANTIBODY IDENTIFICATION AND QUANTIFICATION | SEQTECH DIAGNOSTICS LLC (US) | 2022-10-20 | — | — | WO | claimed |
| CN-108586621-A | Targeting peptides are coupled to the method on recombination lysosomal enzyme | 阿米库斯治疗学公司 | 2018-09-28 | — | — | CN | claimed |
| CN-104160033-B | Method of coupling targeting peptides to recombinant lysosomal enzymes | 阿米库斯治疗学公司 | 2018-06-01 | — | — | CN | claimed |
| US-20260062718-A1 | CELL MEMBRANE PENETRATING CONJUGATES FOR GENE EDITING | CYGENICA LTD (IE) | 2026-03-05 | — | — | US | disclosed |
| US-12517133-B2 | Macromolecule analysis employing nucleic acid encoding | DF PEPTIDE ACQUISITION LLC | 2026-01-06 | — | — | US | disclosed |
| US-12467049-B2 | Methods and kits using nucleic acid encoding and/or label | DF PEPTIDE ACQUISITION LLC | 2025-11-11 | — | — | US | disclosed |
| US-12331310-B2 | Cell membrane penetrating conjugates for gene editing | CYGENICA LIMITED (IE) | 2025-06-17 | — | — | US | disclosed |
| US-12320813-B2 | Macromolecule analysis employing nucleic acid encoding | Encodia, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250164499-A1 | MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODING | DF PEPTIDE ACQUISITION LLC | 2025-05-22 | — | — | US | disclosed |
| EP-3704249-B1 | KITS FOR ANALYSIS USING NUCLEIC ACID ENCODING AND/OR LABEL | ENCODIA INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12292446-B2 | Kits for analysis using nucleic acid encoding and/or label | Encodia, Inc. (US) | 2025-05-06 | — | — | US | disclosed |
| EP-1351991-A2 | TERNARY BIOMOLECULE/POLYMER/SURFACE-BASED IMMOBILIZATION SYSTEMS | Schwartz, David A. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030186845-A1 | Compositions for preventing urinary calculus | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1323433-A1 | COMPOSITIONS FOR PREVENTING URINARY CALCULUS | Nihon Medi-Physics Co., Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-20020146504-A1 | Ternary biomolecule/polymer/surface-based immobilization systems | AUDAX PRIVATE DEBT LLC, AS AGENT | 2002-10-10 | — | — | US | disclosed |
| WO-2002057422-A2 | TERNARY BIOMOLECULE/POLYMER/SURFACE-BASED IMMOBILIZATION SYSTEMS | SCHWARTZ DAVID A (US) | 2002-07-25 | — | — | WO | disclosed |
| US-6217845-B1 | IMAGING; THERAPY | ANORMED, INC. (CA) | 2001-04-17 | — | — | US | disclosed |
| EP-0384769-B1 | Protein labelling | JOHNSON MATTHEY PLC (GB) | 1996-04-24 | — | — | EP | disclosed |
| US-5420285-A | Imaging for medicine | JOHNSON MATTHEY, INC. (US) | 1995-05-30 | — | — | US | disclosed |
| EP-0384769-A2 | Protein labelling | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020146504-A1 | Ternary biomolecule/polymer/surface-based immobilization systems | EPCAM, DNPEP, ANPEP | MAPK1 3974/4885NNMT 1358/4885HCAR3 467/4885 |
| US-20260062718-A1 | CELL MEMBRANE PENETRATING CONJUGATES FOR GENE EDITING | ZFR, ZFX, ZKSCAN2 | MAPK1 4517/4885NNMT 1442/4885HCAR3 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.